Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins ...

It's the superstars of one of B&T's favourite channels - brand experience. Or brand experience with the free sample.

Minds + Assembly, a 2024 MM+M Agency 100 honoree, acquired HashtagHealth, a social media agency focused on healthcare brands. Minds + Assembly also ... joined the Network Advertising Initiative.

The state’s Democratic governor Kathy Hochul on Thursday confirmed a $9 daytime charge for drivers in certain areas of Manhattan would be implemented in January 2025, a lower toll than the $15 ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...

Alzheimer's wonder drugs aren't yet delivering on their promise. American researchers have come up with a brand new idea, a ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

"Samsung Biologics inks $668m manufacturing deal with European pharma " was originally created and published by ...

Viehbacher, “Biogen”) announced today a positive opinion has been received ... About lecanemab (generic name, brand name: Leqembi ®) Lecanemab is the result of a strategic research alliance between ...